AMSは北大発認定スタートアップ企業です

AMS Planning, Inc.

AMS to Launch Joint Research on 225Ac
Radiopharmaceutical Waste Safety with Kyoto University

Collaborative Study to Generate Scientific Data for Improving Alpha Emitter Waste Management Practices
July 8 , 2025 – Tokyo, Japan
AMS has commenced a joint research project with Kyoto University’s Agency for Health, Safety and Environment (Radiation Control Department), under the leadership of Professor Hiroyuki Kimura to study the environmental behavior and containment characteristics of Actinium-225 (225Ac) and its decay products. The aim is to generate foundational adsorption data that will inform the development of safe, compliant, and practical waste management protocols in clinical settings where 225Ac radiopharmaceuticals are administered.

Research Objectives

This academic–industry collaboration focuses strictly on scientific evaluation, rather than co-development of commercial products. The research will involve:
  • Identifying adsorption media suitable for 225Ac and its decay chain isotopes
  • Evaluating the performance of selected materials against 225Ac-labeled compounds such as 225Ac-PSMA and 225Ac-DOTATATE
  • Conducting controlled experiments using artificial waste matrices (e.g., model urine)
  • Generating data to support compliance with Japan’s strict radioactive emission limits

Addressing a Critical Safety Challenge

While 225Ac-based targeted alpha therapies (TAT) offer transformative potential for cancer treatment, they introduce significant challenges in radiation protection. These include:
  • High internal radiotoxicity due to alpha emissions
  • Generation of multiple hazardous daughter nuclides
  • Extremely low regulatory thresholds, with air concentration limits roughly 10,000 times stricter than 177Lu
  • Potential aerosol release via patient exhalation, requiring proactive safety strategies
Professor Kimura noted:
“As the clinical use of alpha emitters expands, it becomes increasingly important to verify safe and scientifically sound approaches to managing radioactive waste. This joint research will support that goal without imposing undue operational burdens on medical facilities.”

AMS’s Filtration System as the Testing Platform

AMS contributes to the study its BSL-177 column filtration system, originally designed and validated for 177Lu waste. This system efficiently adsorbs radionuclides from high-activity urine, minimizes breakthrough, and operates in a compact, scalable format. The purpose of this research is to evaluate how effectively this existing AMS system can be adapted to manage 225Ac-related waste. The study will focus on independent scientific validation of sorbent behaviors under relevant test conditions.

Yuichiro Sugawara, CEO of AMS, commented:
“We are pleased to work with Kyoto University on this important research initiative. By combining academic expertise with our field-tested filtration technology, we hope to deepen the scientific understanding of Actinium-225 behavior and contribute to safer practices in clinical nuclear medicine.”

Contact Information:
Kyoto University – Radiation Control Department
Prof. Hiroyuki Kimura
Agency for Health, Safety and Environment
Website: https://www.esho.kyoto-u.ac.jp/

AMS
Email: info@ams-plan.com
Website: https://www.ams-plan.com